XNAS
CHEK
Market cap4mUSD
Apr 10, Last price
0.71USD
1D
4.65%
1Q
-53.83%
Jan 2017
-99.87%
IPO
-99.95%
Name
Check Cap Ltd
Chart & Performance
Profile
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. The company was incorporated in 2004 and is based in Isfiya, Israel.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | |||||||||
Cost of revenue | 18,056 | 20,439 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (18,056) | (20,439) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 146 | ||||||||
Tax Rate | |||||||||
NOPAT | (18,056) | (20,585) | |||||||
Net income | (17,568) -8.76% | (19,254) 12.65% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 8,850 | ||||||||
BB yield | -70.93% | ||||||||
Debt | |||||||||
Debt current | 337 | ||||||||
Long-term debt | 1,591 | ||||||||
Deferred revenue | |||||||||
Other long-term liabilities | 94 | ||||||||
Net debt | (24,756) | (39,771) | |||||||
Cash flow | |||||||||
Cash from operating activities | (16,954) | (18,707) | |||||||
CAPEX | (83) | (486) | |||||||
Cash from investing activities | 21,356 | (12,508) | |||||||
Cash from financing activities | 8,850 | ||||||||
FCF | (15,406) | (20,487) | |||||||
Balance | |||||||||
Cash | 24,756 | 41,699 | |||||||
Long term investments | |||||||||
Excess cash | 24,756 | 41,699 | |||||||
Stockholders' equity | (61,115) | (43,629) | |||||||
Invested Capital | 84,802 | 85,999 | |||||||
ROIC | |||||||||
ROCE | |||||||||
EV | |||||||||
Common stock shares outstanding | 5,849 | 5,672 | |||||||
Price | 2.08 -5.45% | 2.20 -83.70% | |||||||
Market cap | 12,165 -2.50% | 12,478 -77.67% | |||||||
EV | (12,591) | (27,293) | |||||||
EBITDA | (17,844) | (20,035) | |||||||
EV/EBITDA | 0.71 | 1.36 | |||||||
Interest | 13 | 12 | |||||||
Interest/NOPBT |